Havas SA/€HAVAS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Havas SA
- Ticker
- €HAVAS
- Sector
- Communication
- Primary listing
- AEX
- Employees
- 22,960
- Headquarters
- Puteaux, France
- Website
- www.havas.com
Havas SA Metrics
BasicAdvanced
€1.7B
8.40
€2.01
-
€0.80
4.73%
Price and volume
Market cap
€1.7B
52-week high
€19.55
52-week low
€14.02
Average daily volume
77K
Dividend rate
€0.80
Financial strength
Current ratio
0.805
Quick ratio
0.762
Long term debt to equity
0.116
Total debt to equity
0.356
Dividend payout ratio (TTM)
40.20%
Interest coverage (TTM)
35.60%
Profitability
EBITDA (TTM)
395
Gross margin (TTM)
31.39%
Net profit margin (TTM)
6.81%
Operating margin (TTM)
12.15%
Effective tax rate (TTM)
29.71%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
3.30%
Return on equity (TTM)
12.17%
Valuation
Price to earnings (TTM)
8.396
Price to revenue (TTM)
0.567
Price to book
0.9
Price to tangible book (TTM)
-1.91
Price to free cash flow (TTM)
4.97
Free cash flow yield (TTM)
20.12%
Free cash flow per share (TTM)
3.4
Dividend yield (TTM)
4.73%
Forward dividend yield
4.73%
Growth
Revenue change (TTM)
0.55%
Earnings per share change (TTM)
20.72%
10-year revenue growth (CAGR)
2.69%
10-year earnings per share growth (CAGR)
-7.05%
10-year dividend per share growth (CAGR)
18.22%
What the Analysts think about Havas SA
Analyst ratings (Buy, Hold, Sell) for Havas SA stock.
Analyst projections of the future price of Havas SA stock.
Bulls say / Bears say
North America remains a clear growth engine: organic revenue rose 7.5% in Q3, with Media and Creative benefiting from earlier client wins. That strength helped offset weaker regions. (Havas)
Eight bolt-on deals completed in the first nine months, adding 3.2 percentage points to Q3 net-revenue growth. Havas says acquired agencies typically earn above-group-average margins, which could also support profitability. (Havas)
Adjusted EBIT margin improved by 30 basis points in H1 to 11%. Havas maintained its 2026 margin target of 13.2%–13.5% and its 2028 target of 14%–15%, giving it scope to grow earnings if achieved. (Havas)
Underlying growth is easing: Q3 organic growth slowed to 2.4% from 3.8% a year earlier, while nine-month growth was 2.5% against 2.8%. Acquisitions and currency made up much of the reported 7.2% Q3 increase in net revenue. (Havas)
Regional demand is uneven: Asia Pacific and Africa contracted 6.7% in Q3 and Latin America fell 4.3%. Havas Health was also hurt by fewer US product launches after some drugs did not progress following Phase III trial results. (Havas)
Upside may be limited by the business mix and valuation: Goldman cited modest structural growth in Creative and a lack of scale in US Media when it rated Havas neutral. JPMorgan also said the share re-rating left limited scope for positive earnings surprises. (Yahoo Finance, MarketScreener Australia)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.
Havas SA Financial Performance
Revenues and expenses
Havas SA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Havas SA
AllUSDEUR
Fund name | Fund size | €HAVAS weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.06% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.